Ensysce Biosciences (ENSC) Receivables - Other (2021 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Receivables - Other of $420345.0 for Q4 2025, up 238.67% year-over-year from $124115.0 in Q4 2024, and up 9429.47% quarter-over-quarter from $4411.0 in Q3 2025.
Ensysce Biosciences (ENSC) Receivables - Other (2021 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Receivables - Other for 5 consecutive years, with $420345.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Other rose 238.67% year-over-year to $420345.0; the TTM figure through Dec 2025 stood at $420345.0 (up 238.67% YoY), while the FY2025 annual figure was $420345.0, up 238.67% from the prior year.
- Receivables - Other grew to $420345.0 in Q4 2025 per ENSC's latest filing, from $4411.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.8 million in Q3 2024 and bottomed at $4411.0 in Q3 2025.
- Historically, Receivables - Other has averaged $346742.2 across 5 years, with a median of $140813.0 in 2022.
- Annual changes were most pronounced in 2024 — Receivables - Other jumped 1554.76% — and 2025, when it tumbled 99.75%.
- Ensysce Biosciences' Receivables - Other stood at $441721.0 in 2021, then sank by 37.33% to $276821.0 in 2022, then slumped by 64.76% to $97561.0 in 2023, then gained by 27.22% to $124115.0 in 2024, then surged by 238.67% to $420345.0 in 2025.
- Business Quant data shows ENSC's Receivables - Other at $420345.0 in Q4 2025, $4411.0 in Q3 2025, and $1.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Ensysce Biosciences | 927,560.60 | -3.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 420,345.00 |
| Dec 31, 2025 | 420,345.00 |
| Sep 30, 2025 | 4,411.00 |
| Sep 30, 2025 | 4,411.00 |
| Jun 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 22,002.00 |
| Mar 31, 2025 | 22,002.00 |
| Dec 31, 2024 | 124,115.00 |
| Dec 31, 2024 | 124,115.00 |
| Sep 30, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Jun 30, 2024 | 224,223.00 |
| Jun 30, 2024 | 224,223.00 |
| Mar 31, 2024 | 96,224.00 |
| Mar 31, 2024 | 96,224.00 |
| Dec 31, 2023 | 97,561.00 |
| Dec 31, 2023 | 97,561.00 |
| Sep 30, 2023 | 107,738.00 |
| Sep 30, 2023 | 107,738.00 |